title: Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission.
abstract: Scarce data exist on the relationship of C-reactive protein (CRP) or plasminogen activator inhibitor-1 (PAI-1) to the occurrence of heart failure (HF) or cardiogenic shock (CS) after acute myocardial infarction (AMI) and on the relationship between these biomarkers and mortality in CS patients. Thus, we compared high-sensitivity CRP and PAI-1 antigen plasma levels on admission among 3 age- and gender-matched AMI patients groups (consisting of 60 patients with CS, 60 with HF, and 60 without HF on admission), after determining that PAI-1 levels did not vary significantly diurnally in these groups by comparing the data among subgroups which were divided according to admission time within the groups. For CS patients, we also conducted regression analyses to examine the relations of these biomarkers to mortality. CRP levels both in CS (P < 0.001) and HF (P < 0.05) patients were significantly higher compared to those without HF, PAI-1 levels in CS patients were significantly higher compared to both those with (P < 0.05) and without HF (P > 0.01), and CRP and PAI-1 were independent predictors of in-hospital (Odds ratio [OR] = 6.12, 95% confidence intervals [95%CI] = 1.47-25.54 and OR = 5.92, 95%CI = 1.31-26.77, respectively) and 1-year mortality (OR = 5.53, 95%CI = 1.21-25.17 and OR = 5.48, 95%CI = 1.09-27.52, respectively) in CS patients. In conclusion, at admission, CRP is associated with the occurrence of CS and HF and PAI-1 is associated with the occurrence of CS after AMI, and they are of prognostic value in CS complicating AMI.
authors.affiliation: Department of Cardiology, Mersin University School of Medicine, Mersin, Turkey.
authors.forename: Mehmet Necdet
authors.initials: MN
authors.lastname: Akkus
authors.forename: Gurbuz
authors.initials: G
authors.lastname: Polat
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yurtdas
authors.forename: Burak
authors.initials: B
authors.lastname: Akcay
authors.forename: Neslihan
authors.initials: N
authors.lastname: Ercetin
authors.forename: Dilek
authors.initials: D
authors.lastname: Cicek
authors.forename: Oben
authors.initials: O
authors.lastname: Doven
authors.forename: Nehir
authors.initials: N
authors.lastname: Sucu
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D016001:Confidence Intervals; D004562:Electrocardiography; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000209:etiology / Q000401:mortality; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000401:mortality; D009391:Nephelometry and Turbidimetry; D016017:Odds Ratio; D010343:Patient Admission; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D012770:Shock, Cardiogenic / Q000097:blood* / Q000209:etiology / Q000401:mortality; D015996:Survival Rate; D014421:Turkey / Q000453:epidemiology
chemical_list: D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D002097:C-Reactive Protein